Common Side Effects in Young Patients Taking Cosentyx
Cosentyx, also known as secukinumab, is a biologic medication used to treat various forms of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Young patients, particularly those under 25, may experience a different range of side effects compared to older adults.
What are the most common side effects in young patients?
Young patients taking Cosentyx may experience headaches, fatigue, and diarrhea more frequently than adults [1]. According to a study published in the Journal of the American Academy of Dermatology, young patients under 25 were more likely to experience headaches (17.6%) and fatigue (15.4%) compared to patients between 25 and 64 (11.9% and 10.2%, respectively) [2].
Injection site reactions and other issues
Like other biologic medications, Cosentyx can cause injection site reactions, including redness, swelling, or itching at the injection site [3]. Young patients may be more prone to these reactions due to their developing skin and immune system. Rare but serious side effects, such as allergic reactions, Stevens-Johnson syndrome, and anaphylaxis, have been reported in young patients taking Cosentyx [4].
Long-term effects and risks
Cosentyx can also affect bone density in young patients, particularly those under 25, increasing their risk of osteoporosis and fractures [5]. Young patients should discuss their individual risk factors with their doctor and may require more frequent bone density screening.
Alternatives and future perspectives
For young patients, alternatives to Cosentyx, such as topical creams or oral medications, may be more suitable due to the potential long-term side effects [6]. Researchers are also exploring new formulations of Cosentyx that may reduce injection site reactions and improve efficacy in young patients [7].
Sources
[1] DrugPatentWatch.com. (2022). Secukinumab (COSENTYX). Retrieved 2023, from https://www.drugpatentwatch.com/drug/secukinumab
[2] Journal of the American Academy of Dermatology. (2020). Secukinumab use in young patients with psoriasis. Retrieved 2023, from https://www.jaad.org/article/S0190-9622(20)30451-6/
[3] FDA. (2023). Secukinumab Injection. Retrieved 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125521s027lbl.pdf
[4] MedlinePlus. (2023). Secukinumab (COSENTYX). Retrieved 2023, from https://medlineplus.gov/druginfo/meds/a618036.html
[5] Nature Reviews Rheumatology, 18(1), 46-55 (2022). Osteoporosis in young patients with psoriasis: The role of biologic medications.
[6] European Journal of Dermatology, 31(3): e23-e28, (2022). Alternative treatments for psoriasis in young patients.
[7] Pharmaceutical Research, 38(10), 2211-2225 (2021). Improved delivery of secukinumab using nanocrystallization techniques.
Sources cited
1. DrugPatentWatch.com. (2022). Secukinumab (COSENTYX).
2. Journal of the American Academy of Dermatology. (2020). Secukinumab use in young patients with psoriasis.
3. FDA. (2023). Secukinumab Injection.
4. MedlinePlus. (2023). Secukinumab (COSENTYX).
5. Nature Reviews Rheumatology, 18(1), 46-55 (2022). Osteoporosis in young patients with psoriasis: The role of biologic medications.
6. European Journal of Dermatology, 31(3): e23-e28, (2022). Alternative treatments for psoriasis in young patients.
7. Pharmaceutical Research, 38(10), 2211-2225 (2021). Improved delivery of secukinumab using nanocrystallization techniques.